Phase 3
Completed N=40
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Source: ClinicalTrials.gov NCT05878067 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score — -6.8 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants.
ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day, open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around 40 participants will be enrolled in 1 site in the United States.
Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score |
-6.8 | — |
| SECONDARY Patient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale) |
76.4; 77.1; 81.3; 77.5; 84.1; 82.0 | — |
| SECONDARY Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444 |
-10.1 | — |
Eligibility Criteria
Inclusion Criteria
- Had used artificial tears for dry eyes within the past year
- OSDI score of ≥ 18 and ≤ 65 (based upon a 0 to 100 scale) at Screening and Baseline Visits Three consecutive tear breakup time (TBUT) tests ≤ 10 seconds in at least 1 eye at Day -7 (screening)
- Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that was related to dry eye in at least 1 eye at both at Screening and Baseline Visits
Exclusion Criteria
- Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)
- Known allergy or sensitivity to the study products or their components
- Schirmer Test (with anesthesia) ≤ 2 mm in either eye at Screening Visit
- Participant anticipated contact lens wear during the study, or the participant had worn contact lenses in the last 3 months prior to Screening Visit
Data sourced from ClinicalTrials.gov (NCT05878067). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.